Inclusion Criteria:  Subjects considered as healthy by the investigator based on medical history, clinical examination, laboratory results and ECG (blood sampling for laboratory assessments and ECG should be done at V0 and only after signed informed consent) Subjects who, according to the investigator, can and will comply with the requirements of the protocol and are available for all scheduled visits at the investigational site. Healthy male or female aged between 20 and 79 (included) years Self-declared Han ethnicity for 3 generations Body mass index (BMI) of ≥ 18.5 and ≤ 27.0 kg/m² Ability to give their informed consent in writing Must understand spoken Cantonese and written Chinese  Exclusion Criteria:  Participation in another clinical study in the last 3 months in which the subject has been exposed to an investigational product (pharmaceutical product or placebo or medical device) or concurrent participation in another clinical study during the study period Not current participants enrolled in the FAMILY Cohort First-degree relative to previously recruited individuals in the study cohort For women: pregnant or breastfeeding or intending to become pregnant or peri-menopausal [Peri-menopausal women as defined by menstrual irregularity: either a change in the menstrual cycle length of more than seven days (early perimenopause) or two or more missed periods with an interval of 60 days or more between periods (late perimenopause) (Stages of Reproductive Aging Workshop, STRAW)] Any physical exercise within the last 4 hours before inclusion (V1) Subjects following a special diet for medical reasons as prescribed by a general practitioner or dietician (e.g. calorie-restricted or weight-loss diet for significant overweight, cholesterol-lowering diet or subjects suffering from any clinically diagnosed food allergy or intolerance) Recurrent binge drinking (drinking at least 5 cans of beer, 5 glasses of table wines or 5 pegs of spirits on a single occasion), >2 episodes within 3 months before inclusion Illicit drug use or substance abuse within 3 months before inclusion Presence of evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to participate in the study satisfactorily.  Severe/chronic/recurrent pathological conditions, among them:  10.1. Past or present diagnosed cancer, lymphoma, leukaemia  10.2. Personal history of organ transplant  10.3. Congenital or acquired immune deficiency (any confirmed or suspected immunosuppressive or immunodeficient condition, including a history of HIV infection)  10.4. Personal history of auto-immune diseases requiring or having previously required treatment (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sarcoidosis, Ankylosing Spondylitis, Autoimmune Haemolytic Anaemia, Autoimmune Thrombocytopenic Purpura, Crohn's Disease, Psoriasis, Scleroderma, Wegener's Granulomatosis, Type I Diabetes, Thyroiditis etc.)  10.5. Splenectomy  10.6. Acute or chronic, clinically significant, as determined by the investigator, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests  10.7. History of clinically significant, as determined by the investigator, neurological disorder of seizures  10.8. Infectious diseases  10.8.1. Chronic infection (e.g. HIV, hepatitis B virus, hepatitis C virus…) or current acute infection (including COVID-19) or past acute infection based on investigator's judgment within the last 3 months,  10.8.2. Presence of a rectal temperature ≥38.4°C, or axillary temperature ≥37.5°C, or intra-auricular temperature ≥38.4 °C, or buccal temperature ≥38°C on the scheduled date of inclusion,  10.8.3. Subject receiving (currently or in the last 3 months) antibiotics, intestinal, nasal or respiratory antiseptics.  10.9. Severe High Blood Pressure, defined as systolic BP≥160 mmHg and/or diastolic BP≥100 mmHg (2020 International Society of Hypertension Global Hypertension Practice Guidelines, grade 2 hypertension). Treated and controlled high blood pressure is allowed.  10.10. Type II diabetes mellitus requiring treatment with any medication. Diabetes mellitus treated by exercise and diet control only is permitted.  10.11. Chronic renal impairment as defined by Renal Insufficiency: glomerular filtration rate (GFR) <60 mL/min/1.73 m²16  10.12. Chronic bone disease as treated by bisphosphonates  10.13. Any significant disorder of coagulation or treatment with direct oral anticoagulants (DOACs) or warfarin derivatives or heparin or antiplatelet medications within 2 months preceding inclusion.  10.14. Dermatologic conditions: any current dermatological disorder that is severe enough to prevent skin biopsy (e.g. eczema, psoriasis, acute or chronic dermatitis)  10.15. Severe acute and chronic allergy  10.15.1. Severe Asthma defined as asthma that is uncontrolled despite adherence with optimized high dose inhaled corticosteroid- long-acting beta2-agonist (ICS-LABA) therapy and treatment of contributory factors, or that worsens when high dose treatment is decreased,  10.15.2. Severe food allergy, as defined by a history of giant urticaria, Quincke oedema or anaphylactic shock,  10.15.3. Severe insect bite allergy with a history of giant urticaria, Quincke oedema or anaphylactic shock,  10.15.4. Atopic dermatitis treated with medication.  Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within the 6 months before the inclusion. For corticosteroids, this will mean a dose equivalent to 20 mg/day of prednisone or equivalent for > 2 weeks (inhaled and topical steroids allowed) Chronic administration of NSAIDs, including aspirin: prolonged intake (> 2 weeks) within 6 months before the study or any intake [exception for low dose aspirin: maximum 250mg/daily] Receipt of any vaccination 6 weeks before the inclusion or planning to receive any vaccination during the study Receipt of blood products or immunoglobulins within 3 months before the inclusion or planning to receive blood products or immunoglobulins during the study Haemoglobin measurement less than 10.0 g/dL for women and less than 11.5 g/dL for men Platelet count less than 120.000/mm3 alanine aminotransferase (ALAT) and/or aspartate transaminase (ASAT) > 3 times the upper limit of the norm (ULN)